Validating Restricted Mean Survival Time Estimates From Reconstructed Kaplan-Meier Data Against Original Trial Individual Patient Data From Trials Conducted by the Canadian Cancer Trials Group-Reference-Cited by-同舟云学术

Validating Restricted Mean Survival Time Estimates From Reconstructed Kaplan-Meier Data Against Original Trial Individual Patient Data From Trials Conducted by the Canadian Cancer Trials Group

Published:2022-07 Issue:7 Volume:25 Page:1157-1164
ISSN:1098-3015
Container-title:Value in Health
language:en
Short-container-title:Value in Health

Author:

Everest Louis,Blommaert Scott,Tu Dongsheng,Pater Joseph L.,Hay Annette,Cheung Matthew C.,Chan Kelvin K.W.

Funder

Canadian Cancer Society Research Institute

Publisher

Elsevier BV

Subject

Public Health, Environmental and Occupational Health,Health Policy

Reference25 articles.

1. Outcomes and endpoints in trials of cancer treatment: the past, present, and future;Wilson;Lancet Oncol,2015

2. The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt;Royston;Stat Med,2011

3. The hazards of hazard ratios [published correction appears in Epidemiology. 2011;22(1):134];Hernán;Epidemiology,2010

4. Statistical issues and challenges in immuno-oncology;Chen;J Immunother Cancer,2013

5. Do immune checkpoint inhibitors need new studies methodology?;Ferrara;J Thorac Dis,2018

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tissue mapping by cardiac magnetic resonance imaging for the prognostication of cardiac amyloidosis: A systematic review and meta-analysis;International Journal of Cardiology;2024-05

2. Efficacy of Immune Checkpoint Inhibitors vs. Tyrosine Kinase Inhibitors/Everolimus in Adjuvant Renal Cell Carcinoma: Indirect Comparison of Disease-Free Survival;Cancers;2024-01-28

3. Time-Dependent Changes in Risk of Progression During Use of Bevacizumab for Ovarian Cancer;JAMA Network Open;2023-08-02

4. Reply to T.A. Lin et al;Journal of Clinical Oncology;2023-06-01

5. Bevacizumab in ovarian cancer: time-dependent changes in risk of progression;2023-02-17